Elicio Therapeutics (ELTX) Current Deferred Revenue (2020 - 2025)

Elicio Therapeutics (ELTX) has reported Current Deferred Revenue for 6 consecutive years, with $680000.0 the latest figure, recorded in Q1 2025.

• For the quarter ending Q1 2025, Current Deferred Revenue rose 8.45% year-over-year to $680000.0; the trailing twelve-month figure through Mar 2025 stood at $680000.0 (up 8.45% YoY), and the FY2024 full-year result was $1.2 million, up 68.44% from the prior year.
• Current Deferred Revenue slipped to $680000.0 in Q1 2025 per ELTX's latest filing, from $1.2 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $5.2 million in Q2 2021 and bottomed at $400000.0 in Q2 2024.
• Historically, Current Deferred Revenue has averaged $1.8 million across 5 years, with a median of $1.3 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Current Deferred Revenue sank 82.78% in 2022, then surged 68.44% in 2024.
• Over 5 years, Current Deferred Revenue stood at $2.3 million in 2021, then sank by 37.59% to $1.4 million in 2022, then sank by 51.67% to $694000.0 in 2023, then soared by 68.44% to $1.2 million in 2024, then slumped by 41.83% to $680000.0 in 2025.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $680000.0, $1.2 million, and $1.3 million for Q1 2025, Q4 2024, and Q3 2024 respectively.